A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2017
At a glance
- Drugs LHC-165 (Primary) ; Spartalizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 03 Nov 2017 Planned End Date changed from 16 Jan 2021 to 7 Feb 2021.
- 03 Nov 2017 Planned primary completion date changed from 16 Jan 2021 to 7 Feb 2021.
- 03 Nov 2017 Planned initiation date changed from 21 Nov 2017 to 13 Dec 2017.